靶向间皮素免疫治疗实体瘤的研究进展

Progress in Immunotherapies Targeted to Mesothelin against Solid Tumors

间皮素(Mesothelin)是一种肿瘤相关抗原,这一糖蛋白在超过30%的肿瘤组织中高表达,仅在少量正常组织中低水平表达,是目前研究较多的癌症免疫治疗靶点。目前有多种靶向Mesothelin的免疫治疗产品在临床试验中显示出很好的安全性,其中细胞治疗近年来发展最为迅速。本文将从Mesothelin的生物学特性、靶向Mesothelin免疫治疗药物的临床试验结果、Mesothelin CAR-T细胞免疫治疗面临的挑战和应对策略等几个方面,介绍以Mesothelin为靶点的实体瘤免疫治疗研究进展。

Mesothelin is a tumor associated antigen,a glycoprotein which is highly expressed in over 30%of cancers and only expressed at low levels in a small amount of normal tissues.It is a widely studied cancer immunotherapy target.At present,a variety of immunotherapeutic products targeting mesothelin have shown good safety in clinical researches,especially adoptive cell therapy targeting mesothelin has been developed rapidly in recent years.This article introduces the research progress and trends of solid tumors immunotherapy targeting mesothelin from several aspects,including biological characteristics of mesothelin,clinical trials results of immunotherapy,as well as challenges and response strategies of CAR-T cell immunotherapy.